Alzheimer’s Biomarkers For Disease Progression Will Be A Hard Road, Experts Say
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A panel of experts discussing challenges in researching disease-progression biomarkers for Alzheimer’s agreed that the heterogeneity and evolving nature of the disease complicate the task and may require large panels of biomarkers – a potentially costly and invasive solution.